Field Trip Health Ltd. to Participate in Upcoming Investor Conferences in May 2022

Field Trip Health Ltd. to Participate in Upcoming Investor Conferences in May 2022

TORONTO, April 29, 2022 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) (“Field Trip”), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip’s management team will participate in two investor conferences in May 2022.

2022 Bloom Burton & Co. Healthcare Investor Conference:
Date: May 2-3, 2022
Location: Toronto
Presentation date & time: May 2, 2022 at 11:00am E.T.
Webcast link: Click here
Registration: Click here

H.C. Wainwright Global Investment Conference:
Date: May 23-26, 2022
Location: Virtual and Miami
Presentation date & time: On-demand starting May 24, 2022 at 7:00am E.T.
Webcast link: Click here
Registration: Click here

The webcast recordings will also be accessible on Field Trip’s investor relations website and can be found here.

Institutional investors interested in scheduling a meeting with Field Trip’s management team, please contact KCSA Strategic Communications at fieldtripIR@kcsa.com.

About Field Trip Health Ltd.

Field Trip is a global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics and our Field Trip Health division building centres for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale, we help people in need with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at https://www.meetfieldtrip.com, https://www.fieldtriphealth.com and https://www.fieldtriphealth.nl.

Follow us on Twitter and Instagram: @fieldtriphealth.

To receive company updates about Field Trip and to be added to the email distribution list please sign up here.

Cautionary Note Regarding Forward-Looking Information  

This release includes forward-looking information (within the meaning of Canadian securities laws and within the meaning of the United States Private Securities Litigation Reform Act of 1995) regarding Field Trip and its business. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of Field Trip and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including those set forth in the Company’s Annual Information Form and other market conditions, economic factors, management’s ability to manage and to operate the business and the equity markets generally. Although Field Trip has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Additional information relating to Field Trip, including its Annual Information Form, can be located on the SEDAR website at www.sedar.com and on the EDGAR section of the SEC’s website at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities.

Neither the Toronto Stock Exchange, nor its Regulation Services Provider, have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.

CONTACTS:

Investor contacts:
Kathleen Heaney / Sophia Bashford / Tim Regan
KCSA Strategic Communications
fieldtripIR@kcsa.com

Media contacts:
Rachel Moskowitz
Autumn Communications
202-276-7881
press@fieldtriphealth.com

SOURCE Field Trip Health Ltd.

Numinus Announces the Music as Medicine Event Series

Numinus Announces the Music as Medicine Event Series

Music As Medicine by Numinus is a series of Meditative Musical Experiences & Creative Content Featuring Jon Hopkins, East Forest And Superposition    

VANCOUVER, BC, April 29, 2022 /CNW/ – Numinus Wellness (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that it is launching Music As Medicine by Numinus, a series of ceremonial concerts exploring the role music plays in psychedelic-assisted therapy and mental health. Music As Medicine by Numinus will feature a rotating roster of meditative and ambient musicians, including Jon Hopkins, East Forest and Superposition, multimedia art, and immersive guided meditations.

Numinus Announces the Music as Medicine Event Series (CNW Group/Numinus Wellness Inc.)
Numinus Announces the Music as Medicine Event Series (CNW Group/Numinus Wellness Inc.)

“Music, community and connection have always played an important role in sacred ceremonies and are an integral component of psychedelic-assisted therapy and integration,” says Payton Nyquvest, Founder and CEO, Numinus. “Through the Music as Medicine by Numinus series, we are celebrating an emerging genre of meditative music and exploring the role that music can play as part of the healing process, while building connection across a community.”

“Psychedelic therapies are moving into legality across the world, and yet it feels like no one is talking about the music that accompanies them,” says Jon Hopkins. “In Indigenous psychedelic ceremonies,” he adds, “the music is as important as the medicine, and has been for thousands of years. Music is how you navigate the space.”  

Following the recent announcement of Numinus’ proposed expansion into the U.S., Music As Medicine by Numinus will be hosted in various cities across the U.S. and Canada, celebrating Numinus’ move into the U.S. and reinforcing its community in its home country of Canada. The first event is in Los Angeles on May 21, 2022 at the renowned venue, Lighthouse Immersive, and will consist of five hours of continuous and entrancing live music and visuals by a line-up of the preeminent artists in this emerging genre: Superposition, Justin Boreta, Matthew Davis’ ambient project and East Forest.  L.A.-based multimedia art studio Strangeloop, known for their captivating visuals for artists such as Lil NasX, Flying Lotus, and The Weeknd, will be fully enveloping the space with live projection-mapping intended to submerge guests in an all-sensory experience. The event will end with a live, 3D spatial-audio playback of Jon Hopkins‘ most recent, acclaimed album, Music For Psychedelic Therapy, experienced in total darkness, followed by an intimate, live piano performance of “Sit Around the Fire”.

“We are thrilled to be a part of the Music as Medicine by Numinus event series. The intention is to create a safe container for deep listening,” says Justin Boreta. “This is the way this type of music should be experienced.”

“Music to modern humans is like asking a fish what water is. With music more present than ever, I am excited to be fostering spaces that can serve as a spear tip of exploration and experimentation around using music as a tool for inner insight and growth,” says East Forest.

Numinus is also showcasing its Music As Medicine by Numinus concept at DoubleBlind’s Mycelia Festival in Ojai, California, as well as other cities, which will be announced soon. 

Tickets for the L.A. event go on sale Friday, April 29 at www.numinus.com/music-as-medicine-event. More information on the other dates will be released in the coming weeks.About Numinus

Numinus Wellness (TSX: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Learn more at www.numinus.com and follow us on LinkedInFacebookTwitter, and Instagram.Forward-looking statements

This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are “forward-looking statements”. Forward-looking statements can be identified by the use of words such as “expects”, “does not expect”, “is expected”, “believes”, “intends”, “anticipates”, “does not anticipate”, “believes” or variations of these words, expressions or statements, that certain actions, events or results “may”, “could”, “would”, “might” or “will be” taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, dependence on obtaining and maintaining regulatory approvals, including the acquisition and renewal of federal, provincial, municipal, local or other licenses, and any inability to obtain all necessary government authorizations, licenses and permits to operate and expand the Company’s facilities; regulatory or policy changes such as changes in applicable laws and regulations, including federal and provincial legalization, due to fluctuations in public opinion, industry perception of integrative mental health, including the use of psychedelic-assisted therapy, delays or inefficiencies or any other reason; any other factor or development likely to hamper the growth of the market; the Company’s limited operating and profitability track record; dependence on management; the Company’s need for additional financing and the effects of financial market conditions and other factors on the availability of capital; competition, including that of more established and better funded competitors; the impact of the Russia-Ukraine conflict on the global economy; the continued impact of the COVID-19 pandemic; and the need to build and maintain alliances and partnerships, including with research and development companies, customers and suppliers. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company’s efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws.

SOURCE Numinus Wellness Inc.

For further information: Investor Contact: Jamie Kokoska, Vice President, Investor Relations & Communications, jamie.kokoska@numinus.com, +1 833-686-4687; Media Contact: Hilary Strath, Director, Communications, hilary.strath@numinus.com

Music as medicine

Numinus Announces the Music as Medicine Event Series

Numinus Wellness (NUMI) is launching a series of ceremonial concerts called Music As Medicine to explore the role that music plays in psychedelic therapy.

The events will feature meditative and ambient musicians such as Jon Hopkins, East Forest and Superposition, as well as multimedia art and immersive guided meditations.

The first event will be in LA on May 21 – learn more here.

PDF of article

IntelGenx to Participate in the 2022 Bloom Burton & Co. Healthcare Investor Conference

IntelGenx to Participate in the 2022 Bloom Burton & Co. Healthcare Investor Conference

SAINT LAURENT, Quebec, April 26, 2022 (GLOBE NEWSWIRE) — IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that management will present an update on the Company’s business at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, May 3, 2022 at 9:30 a.m. Eastern Time at the Metro Toronto Convention Centre.

The presentation will be broadcast live and archived on the Company’s website at www.intelgenx.com under “Webcasts” in the Investors section.

About IntelGenx

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx’s superior film technologies, including VersaFilm®, DisinteQ, VetaFilm and transdermal VevaDerm, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx’s highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx’s state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit www.intelgenx.com.

Forward-Looking Information and Statements

This document may contain forward-looking information about IntelGenx’s operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx’s plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words “may,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “could,” “would,” and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx’s actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading “Risk Factors” in IntelGenx’s annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Source: IntelGenx Technologies Corp.

For IntelGenx:

Stephen Kilmer
Investor Relations
(647) 872-4849
stephen@kilmerlucas.com

Or

Andre Godin, CPA, CA
President and CFO
IntelGenx Corp.
(514) 331-7440 ext 203
andre@intelgenx.com

Benzinga Psychedelics Capital Conference

Benzinga Psychedelics Capital Conference

Miami, Florida | April 19, 2022

Benzinga Psychedelics Capital Conference

Coming to you live from the Fontainebleau Miami Beach, the Benzinga Psychedelics Capital Conference is bringing together leaders of the BIGGEST publicly-traded Psychedelics companies with investors from across North America.

Join us for a day full of unique networking opportunities, insight on opportunities in this burgeoning space, and a chance to be in the room with the leaders who will take the Psychedelics industry to the next level.

Learn more

CATALYST Summit 2022

CATALYST Summit 2022

Kingston, Ontario | May 20-22, 2022

Use code DAILYM20 to get 20% off! Offer valid until May 6.

CATALYST Summit 2022 will take place IN PERSON at Queen’s University in beautiful Kingston, Ontario, Canada, and ONLINE. We will be hosting a line-up of best-in-class speakers and experts, influencers, and global psychedelics leaders joining us to share their vision of a world WITH Psychedelic Medicine.

VIP ticket holders will have the following access:

  • Front 3 -row seating at all the speaker stages
  • VIP Lounge (w/ food & drinks)
  • VIP Lunch or cocktail events to meet & greet industry leaders and speakers

Catalyst is bringing together key stakeholders of the Canadian psychedelic community, including clinicians, therapists, mental health practitioners, scientists, academic researchers, Canadian and International policymakers, business industry leaders, consumers of psychedelic medicine and supporters.

2022 Speakers include:

  • Paul Stamets
  • Dr. Anthony Bossis
  • Dr. Jane Philpott
  • Dr. Ben Sessa MBBS (MD) BSc MRCPsych
  • Saundra Jain, MA, PsyD, LPC
  • Dr. Erika Dyck
  • Dr. Pamela Kryskow
  • Mark Haden
  • Bruce Sanguin
  • Dr. Shannon Dames
  • Patrick Moher
  • Kelsey Ramsden
  • Trevor Millar
  • Cory Firth
  • Michael Kydd
  • Salimeh Tabrizi, M.Ed
  • Rich Tyo
  • Ian Mitchel
  • Marcus & Amber Capone
  • Crispin Blunt
  • Paul Lewin
  • Ronan Levy
  • Timmy Davis
  • Anne Wagner
  • Sherry Boodram
  • Emma Hapke
  • Senator Larry Campbell

Learn more

Interdisciplinary Conference on Psychedelic Research 2022

Interdisciplinary Conference on Psychedelic Research 2022

Amsterdam, Netherlands | September 22-24, 2022

The Pioneering And Leading Psychedelic Research Conference In Europe

ICPR features world-leading experts from many academic disciplines, including psychiatry, psychology, neuroscience, anthropology, ethnobotany, and philosophy who come together to give a scientific conference for academics, therapists, researchers, clinicians, policymakers, and members of the public. The OPEN Foundation has been organising 5 large and international conferences since 2010.

Learn more

Lester Grinspoon Reconsidered: Celebrating a Pioneer of Drug Policy and a Legacy of Social Change

Lester Grinspoon Reconsidered: Celebrating a Pioneer of Drug Policy and a Legacy of Social Change

Amherst, Massachusetts | June 24, 2022

NEWS Grinspoon Symposium

“Lester Grinspoon Reconsidered: Celebrating a Pioneer of Drug Policy and a Legacy of Social Change,” a symposium honoring the Harvard psychiatrist who became a celebrated advocate for reforming marijuana prohibition laws and for recognizing marijuana’s potential benefits both medicinal and recreational, will take place at the University of Massachusetts Amherst on Friday, June 24. The Robert S. Cox Special Collections and University Archives Research Center (SCUA) and the UMass Amherst Libraries are hosting the day-long event in the Campus Center, on what would have been Grinspoon’s 94th birthday. It will feature the renowned psychologist, neuroscientist, and author Carl Hart, who will give the keynote address. Registration is now open at the symposium website.

Planned with the Grinspoon family and longtime friend and activist Allen St. Pierre, UMass class of 1989, the symposium brings together some of the country’s most prominent experts and activists, many of whom knew Grinspoon, worked with him, or were inspired by his work, and includes those whose work takes a visionary approach to the role that marijuana and psychedelics can play in society. Three panels will explore where drug policy has been, including the journey to (more or less) cultural acceptance; where it is now and impacts on scientific research and business and industry; and what lies ahead for cannabis and psychedelics in medicine, policy, and the culture at large.

Learn more

From Research to Reality: Global Summit on Psychedelic-Assisted Therapies and Medicine

From Research to Reality: Global Summit on Psychedelic-Assisted Therapies and Medicine

Toronto, Ontario | May 27-29, 2022

The First Global Summit of its Kind

We want to shift the action from the research lab to the real-world clinical application, and start making a difference in the lives of those living with mental health and substance use disorders. To this end, researchers, clinicians, policy-makers and people with lived experience will gather at the 2022 international conference in Toronto to break down barriers to progress, share original research, and build a network of knowledge-exchange opportunities.

Learn more